Contraline is a technology company.
Contraline has raised $23.7M across 5 funding rounds.
Contraline has raised $23.7M in total across 5 funding rounds.
Contraline has raised $23.7M in total across 5 funding rounds.
Contraline's investors include Abstract Ventures, LAUNCH, Long Journey Ventures, MBX Capital, Bill Smith, Jaffray Woodriff, ATOMS, Vitalize Venture Group, Fuse, York IE, Aston Motes, Kyle York.
Contraline is a medical device company developing ADAM™, a long-lasting, non-hormonal, and reversible male contraceptive implant using hydrogel technology, often described as the "male IUD."[1][2][3][4] The product targets men and couples seeking effective birth control without hormonal side effects; it serves by injecting a proprietary hydrogel (previously referenced as Echo-V) into the vas deferens via a minimally invasive outpatient procedure, blocking sperm while allowing fluid passage.[1][3] This solves the problem of limited male contraceptive options beyond condoms or vasectomy, aiming for 10+ years of efficacy with reversibility.[1][4] Headquartered in Charlottesville, Virginia, with about 10 employees, Contraline has raised funding through grants (e.g., $1M from Male Contraceptive Initiative in 2020), competition awards, private investment, and venture capital, and remains in the development stage with clinical trials underway.[1][2]
Contraline was founded in 2015 by Kevin Eisenfrats (Co-Founder and CEO) and Dr. John Herr, leveraging advancements in hydrogel technology for vas-occlusion.[1] Eisenfrats, with a background in medical device innovation, leads efforts focused on clinical translation and patient satisfaction; the company emerged from research addressing decades of failed attempts at non-hormonal male contraception.[1][3] Early traction included a $200K grant from the Male Contraceptive Initiative in 2018 and a $1M investment in 2020 to fund clinical trials, marking pivotal moments that propelled development of ADAM™.[1] Based at 1216 Harris Street in Charlottesville, the team has grown to support ongoing trials and hiring, such as for senior design engineers.[2]
Contraline rides the trend toward contraceptive equity and shared reproductive responsibility, addressing the market gap where women bear most long-acting options amid rising demand for male-involved birth control.[1][3] Timing aligns with maturing hydrogel tech and funding for male contraceptives, fueled by societal shifts post-#MeToo and clinical progress (e.g., ongoing trials).[1] Favorable forces include regulatory interest in non-hormonal innovations and a $20B+ global contraception market, where male options remain <10%.[1] The company influences the ecosystem by pioneering the "intra-vas device" (IVD), potentially spurring competitors and normalizing male contraception in medtech hubs like Charlottesville's BioHub.[2][3]
Contraline's clinical trials position it for potential FDA clearance in the late 2020s, with next steps including trial expansion, reversibility data, and commercialization partnerships.[1] Trends like personalized medtech, ultrasound integration, and gender-balanced family planning will accelerate adoption, evolving its influence from niche innovator to catalyst in a male contraceptive market projected to grow 15%+ annually. As the "IUD for men" matures, Contraline could redefine contraception, empowering couples with truly shared options.[4]
Contraline has raised $23.7M across 5 funding rounds. Most recently, it raised $7.0M Series A in November 2022.
| Date | Round | Lead Investors | Other Investors |
|---|---|---|---|
| Nov 1, 2022 | $7.0M Series A | Abstract Ventures, LAUNCH, Long Journey Ventures, MBX Capital, Bill Smith, Jaffray Woodriff | |
| Oct 1, 2021 | $11.0M Series A | Abstract Ventures, ATOMS, LAUNCH, Long Journey Ventures, MBX Capital, Vitalize Venture Group, Bill Smith, Jaffray Woodriff | |
| Sep 1, 2018 | $3.0M Seed | Fuse, York IE, Aston Motes, Kyle York, Sahin Boydas | |
| Mar 1, 2017 | $2.0M Seed | 500 Global, 7BC Venture Capital, Abstract Ventures, Alumni Ventures, Amino Capital, ATOMS, Bling Capital, C2 Investment, Kevin Ding, Founders Fund, Greenoaks Capital, Helium-3 Ventures, Jigsaw VC, Kleiner Perkins, Long Journey Ventures, Practical Venture Capital, Primitive Ventures, Quiet Capital, Rubicon VC, Saga, TNT Venture, Tribe Capital, UpHonest Capital, Vitalize Venture Group, Y Combinator, Elad Gil, Matt Bellamy, Mike Vernal, Samvit Ramadurgam, Scott Banister, Sohail Prasad, Sue Xu | |
| May 1, 2016 | $680K Seed | ATOMS, Vitalize Venture Group |